In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.

●Consolidated net sales totaled 222,584 million yen, an increase of 20,793 million yen (10.3%) year-on-year. Sales in the Mobility & Imaging Business Unit, Fine Chemicals Business Unit, and Life Science Business Unit all outperformed the previous fiscal year.
●Consolidated operating income increased by 13,064 million yen (178.1%) to 20,401 million yen compared to the pre-vious fiscal year.
●Consolidated ordinary income totaled 22,266 million yen, an increase of 9,704 million yen (77.3%) year-on-year. The increase was due to growth in consolidated operating income which exceeded the decrease in foreign exchange gains.
●Profit attributable to owners of parent was 17,508 million yen, an increase of 13,395 million yen (325.6%) year-on-year. The increase was mainly due to a gain on sales of investment securities.

(millions yen)	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03
Total assets	272,679	272,791	285,600	293,571	278,496	294,535	315,459	322,858	363,173	373,708
Net assets	200,492	205,866	220,619	229,043	210,019	228,273	246,425	255,027	270,548	268,520
Liabilities	72,186	66,924	64,980	64,528	68,477	66,261	69,034	67,831	92,624	105,188
Equity ratio	69.3%	71.1%	72.9%	73.6%	75.2%	77.2%	77.8%	78.7%	74.2%	71.6%